socalTECH

NOVEMBER 14, 2013

Monrovia, California-based Xencor has set the initial offering price for its IPO, saying in a filing Thursday morning that it will offer up 10,700,000 shares of its common stock at $7.00 The IPO price is below its initial estimated offering price, which had been between $14.00 and $16.00 and $16.00 Stafford, III.

Pricing 157

Pricing Monrovia Acquisition Marketing 157

socalTECH

DECEMBER 3, 2013

Monrovia-based biopharmaceuticals developer Xencor said this morning that it has priced its IPO, at $5.50 per share, and will start trading today on the NASDAQ Global Market as XNCR. Xencor sold 12,730,000 shares of its common stock in the IPO. Xencor was venture backed by MedImmune Ventures, HealthCare Ventures, and others.

Pricing 138

Pricing Monrovia Acquisition Marketing 138

socalTECH

NOVEMBER 4, 2013

Monrovia, California-based Xencor , the biopharmaceuticals technology developer headed by Bassil Dahiyat, has set its IPO pricing range, saying today in a regulatory filing that it is expecting to price its IPO at between $14.00 and $16.00 The company is looking to trade as XNCR on the NASDAQ Global Market.

Pricing 138

Pricing Monrovia Acquisition Marketing 138

socalTECH

FEBRUARY 11, 2020

Monrovia, California-based AeroVironment , which develops unmanned aerial vehicles, said late Monday that it has received a $8.5M According to AeroVironment, the $8,584,734 firm-fixed-price U.S. military sales contract from an un-named, U.S.

Outsource Development 113

Outsource Development Monrovia Training Sales 113

socalTECH

DECEMBER 1, 2016

Monrovia-based biotechnology developer Xencor has launched a public offering of its common stock, with the aim of raising approximately $110M in funding, the company said on Wednesday. The publicly traded biotechnology developer--which trades on the NASDAQ as XNCR--said it has priced the offering at $24.000 per share.

Monrovia 100

Monrovia Pricing Capital Invest 100